Life sciences debt investor BioPharma Credit said it had entered into a senior secured term loan agreement with Collegium Pharmaceutical. Collegium Pharmaceutical, a publicly traded biopharmaceutical company, was focused on developing and commercializing new medicines for responsible pain management with a current market capitalization of about US$680m. Under the terms of the transaction, the company would invest US$165m in a single drawing and BioPharma-V would invest US$35m in parallel, with the company acting as collateral agent, Biopharma said. The loan would mature in January 2024 and bear interest at 3-month LIBOR plus 7.50% per annum subject to a 2.00% floor along with a one-time additional consideration of 2.50% of the loan amount payable upon funding, it added. At 10:00am: (LON:BPCR) Biopharma Credit Plc share price was 0p at 1p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.